Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial



Khanna, D, Denton, CP, Jahreis, A, van Laar, JM, Frech, TM, Anderson, ME, Baron, M, Chung, L, Fierlbeck, G, Lakshminarayanan, S
et al (show 14 more authors) (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The Lancet, 387 (10038). 2630 - 2640.

This is the latest version of this item.

[img] Text
101101617 SSc Ms rev FINAL Tracked.docx - Accepted Version

Download (7MB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 25 Jan 2019 11:31
Last Modified: 28 Nov 2021 07:10
DOI: 10.1016/S0140-6736(16)00232-4
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3030738

Available Versions of this Item